GlassScriptPhysician profile
Ronald M Goldenberg
NPI 1881682425
$8,147.80
in general payments reported to CMS, 2019-2025
18 companies · $436 in 2025
The $436 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,228 · 2020: $1,537 · 2021: $1,519 · 2022: $898 · 2023: $1,081 · 2024: $449 · 2025: $436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,946.13 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $2,465.07 | 2019-2024 | Xarelto |
| Pfizer INC. | $866.17 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $672.58 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $643.37 | 2019-2021 | |
| Csl Behring | $567.22 | 2022-2025 | Kcentra, Haegarda |
| Portola Pharmaceuticals, LLC | $479.08 | 2019-2020 | |
| Allergan, INC. | $456.57 | 2019-2020 | |
| Melinta Therapeutics, LLC | $425.69 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $379.76 | 2023 | Terlivaz |
| Alexion Pharmaceuticals, INC. | $253.48 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $248.00 | 2019-2025 | Zerbaxa, Recarbrio, Dificid |
| Chiesi USA, INC. | $217.36 | 2019-2021 | |
| Abbvie INC. | $140.40 | 2024-2025 | |
| Glaxosmithkline, LLC. | $127.86 | 2024-2025 | Nucala |
| Gilead Sciences, INC. | $91.34 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fennec Pharmaceuticals, INC. | $68.89 | 2023 | Pedmark |
| Vapotherm INC | $26.31 | 2019 | |
| Nabriva Therapeutics, Plc | $18.65 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Goldenberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.